Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 1 Interventional

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT03315741
View directory record Official record
Conditions
Bronchiolitis Obliterans, Graft Vs Host Disease
Interventions
Pirfenidone 267 MG [Esbriet]
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01027000
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
25
States / cities
Duarte, California • Lewes, Delaware • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

NCT00586443
View directory record Official record
Conditions
Solid Tumors
Interventions
bevacizumab, everolimus, panitumumab
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 30, 2026, 11:21 AM EDT
Completed No phase listed Observational

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Wellesley, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 30, 2026, 11:21 AM EDT
Completed No phase listed Observational

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

NCT01598597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

NCT00979017
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Avastin, Temozolomide, Irinotecan
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 4 Interventional Results available

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

NCT03097068
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Lucentis
Drug
Lead sponsor
Vitreo-Retinal Associates, Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

NCT00047710
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Bevacizumab, Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

NCT00675259
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, carboplatin, nab-paclitaxel, Surgery, Adjuvant chemotherapy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 30, 2026, 11:21 AM EDT
Active, not recruiting Phase 4 Interventional

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Placebo for Ocrelizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
13
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

NCT00486759
View directory record Official record
Conditions
B-cell Lymphoma
Interventions
Bevacizumab, Rituximab, CHOP, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 79 Years
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
La Jolla, California • Whittier, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

NCT00998036
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Temsirolimus, Cisplatin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional

Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients

NCT00127920
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Avastin
Drug
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

NCT01652482
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-fluorouracil, Cetuximab, Irinotecan, Leucovorin, MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller

NCT04092582
View directory record Official record
Conditions
Asthma
Interventions
MTPS9579A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Walnut Creek, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 11:21 AM EDT
Not listed No phase listed Observational

Pulmonary Care and Research Collaborative Patient Registry

NCT05445817
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 30, 2026, 11:21 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

NCT06828991
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Mosunetuzumab, ClonoSEQ
Drug · Device
Lead sponsor
Danielle Wallace
Other
Eligibility
70 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 30, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

NCT00582166
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Ibritumomab Tiuxetan (Zevalin) + Rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NCT01055795
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Bevacizumab, Everolimus and LBH589
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

NCT01435395
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, bevacizumab and bortezomib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 30, 2026, 11:21 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

NCT02044601
View directory record Official record
Conditions
Lung Cancer
Interventions
Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 30, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

NCT01055028
View directory record Official record
Conditions
Angiosarcomas, Soft Tissue Sarcoma
Interventions
Bevacizumab, Paclitaxel
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Santa Monica, California • Stanford, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 30, 2026, 11:21 AM EDT
Completed Phase 2 Interventional

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

NCT05125471
View directory record Official record
Conditions
Arteriovenous Malformations (Extracranial)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 30, 2026, 11:21 AM EDT